Leonel Ochoa-Bayona

Prediction of non-relapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT) is important, especially in older adults. Composite risk models using routine clinical and laboratory parameters have been developed and tested [1,2], but validation is needed. We evaluated a model for NRM in the real-world setting. We included consecutive transplants at the Moffitt Cancer Center 2014 to 2023 with pre-HCT CRP (N = 358). We excluded participants in CTN 1704 (N = 41).